| Intelicare Hospice 41650 Gardenbrook Road, Suite 115, Novi, MI, 48375 | |
| (810) 623-1328 |
News Archive
An interview with Lindy O'Clair, discussing the challenges of studying neuronal systems over time, and the development of an automated platform by Sartorius.
Spherix Incorporated, an innovator in biotechnology for diabetes therapy, and a provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced that it will explore triglycerides as a potential therapeutic opportunity for its D-tagatose therapy, pending a review of data from a Phase 3 clinical trial the Company is conducting on the use of D-tagatose as a treatment for Type 2 diabetes.
Quanterix announced that it will release its financial results for first quarter 2019 after the close of trading on Thursday, May 9, 2019.
The Boston Globe: "A group of Massachusetts mayors, fed up with what they say is legislative inaction on skyrocketing municipal health care costs, has launched a ballot initiative for 2012 aimed at giving cities and towns more flexibility in reducing expensive benefits for employees, retirees, and elected officials" (Murphy, 3/10).
› Verified 4 days ago
| Name | Intelicare Hospice |
|---|---|
| Location | 41650 Gardenbrook Road, Suite 115, Novi, Michigan |
| Hospice ID | 231654 |
| Category | Freestanding Hospice |
| Ownership Type | Proprietary - Corporation |
| Profit Type | FOR PROFIT |
| Accreditation Provider | Community Health Accreditation Partner (CHAP) |
| SSA county code | 680 |
News Archive
An interview with Lindy O'Clair, discussing the challenges of studying neuronal systems over time, and the development of an automated platform by Sartorius.
Spherix Incorporated, an innovator in biotechnology for diabetes therapy, and a provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced that it will explore triglycerides as a potential therapeutic opportunity for its D-tagatose therapy, pending a review of data from a Phase 3 clinical trial the Company is conducting on the use of D-tagatose as a treatment for Type 2 diabetes.
Quanterix announced that it will release its financial results for first quarter 2019 after the close of trading on Thursday, May 9, 2019.
The Boston Globe: "A group of Massachusetts mayors, fed up with what they say is legislative inaction on skyrocketing municipal health care costs, has launched a ballot initiative for 2012 aimed at giving cities and towns more flexibility in reducing expensive benefits for employees, retirees, and elected officials" (Murphy, 3/10).
› Verified 4 days ago
| Quality Measure | Provider Score | National Score |
|---|---|---|
| Patients or caregivers who were asked about treatment preferences like hospitalization and resuscitation at the beginning of hospice care | Not Available | 98.3 |
| Patients or caregivers who were asked about their beliefs and values at the beginning of hospice care | Not Available | 93.6 |
| Patients who were checked for pain at the beginning of hospice care | Not Available | 93.9 |
| Patients who got a timely and thorough pain assessment when pain was identified as a problem | Not Available | 77.7 |
| Patients who were checked for shortness of breath at the beginning of hospice care | Not Available | 97.3 |
| Patients who got timely treatment for shortness of breath | Not Available | 94.6 |
| Patients taking opioid pain medication who were offered care for constipation | Not Available | 93.3 |
News Archive
An interview with Lindy O'Clair, discussing the challenges of studying neuronal systems over time, and the development of an automated platform by Sartorius.
Spherix Incorporated, an innovator in biotechnology for diabetes therapy, and a provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced that it will explore triglycerides as a potential therapeutic opportunity for its D-tagatose therapy, pending a review of data from a Phase 3 clinical trial the Company is conducting on the use of D-tagatose as a treatment for Type 2 diabetes.
Quanterix announced that it will release its financial results for first quarter 2019 after the close of trading on Thursday, May 9, 2019.
The Boston Globe: "A group of Massachusetts mayors, fed up with what they say is legislative inaction on skyrocketing municipal health care costs, has launched a ballot initiative for 2012 aimed at giving cities and towns more flexibility in reducing expensive benefits for employees, retirees, and elected officials" (Murphy, 3/10).
› Verified 4 days ago
| Home Health Aides | 1 |
| Medical Social Workers | 0.5 |
| Physicians | 0.5 |
| Registered Nurses | 2 |
| Other Personnel | 1 |
| Total Employees | 5 |
|---|
News Archive
An interview with Lindy O'Clair, discussing the challenges of studying neuronal systems over time, and the development of an automated platform by Sartorius.
Spherix Incorporated, an innovator in biotechnology for diabetes therapy, and a provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced that it will explore triglycerides as a potential therapeutic opportunity for its D-tagatose therapy, pending a review of data from a Phase 3 clinical trial the Company is conducting on the use of D-tagatose as a treatment for Type 2 diabetes.
Quanterix announced that it will release its financial results for first quarter 2019 after the close of trading on Thursday, May 9, 2019.
The Boston Globe: "A group of Massachusetts mayors, fed up with what they say is legislative inaction on skyrocketing municipal health care costs, has launched a ballot initiative for 2012 aimed at giving cities and towns more flexibility in reducing expensive benefits for employees, retirees, and elected officials" (Murphy, 3/10).
› Verified 4 days ago
| Others | 0.45 |
| Total Volunteers | 0.45 |
|---|
News Archive
An interview with Lindy O'Clair, discussing the challenges of studying neuronal systems over time, and the development of an automated platform by Sartorius.
Spherix Incorporated, an innovator in biotechnology for diabetes therapy, and a provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced that it will explore triglycerides as a potential therapeutic opportunity for its D-tagatose therapy, pending a review of data from a Phase 3 clinical trial the Company is conducting on the use of D-tagatose as a treatment for Type 2 diabetes.
Quanterix announced that it will release its financial results for first quarter 2019 after the close of trading on Thursday, May 9, 2019.
The Boston Globe: "A group of Massachusetts mayors, fed up with what they say is legislative inaction on skyrocketing municipal health care costs, has launched a ballot initiative for 2012 aimed at giving cities and towns more flexibility in reducing expensive benefits for employees, retirees, and elected officials" (Murphy, 3/10).
› Verified 4 days ago
| Intelicare Hospice Location: 41650 Gardenbrook Road, Suite 115, Novi, Michigan, 48375 Phone: (810) 623-1328 |